• Vaccine Name: NDV-VF/S vaccine
• Target Pathogen: SARS-CoV
• Target Disease: Severe Acute Respiratory Syndrome (SARS)
• Vaccine Ontology ID: VO_0005148
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Monkey
• Antigen: Full-length 1,255-aa SARS-CoV S protein (DiNapoli et al., 2007)
• Immunization Route: intranasal immunization

Monkey Response

• Host Strain: African Green Monkey
• Vaccination Protocol: Monkeys were vaccinated with 107 pfu of the recombinant virus days 0 and 28 (the two-dose groups) or on day 0 only (the one-dose group). (DiNapoli et al., 2007)
• Immune Response: Induced neutralizing antibodies, Produced S-specific antubodies, Increase in CD8+ T cells creating IFN-γ and TNF-α1 (DiNapoli et al., 2007)
• Challenge Protocol: 28 days after the second dose, they were challenged by the i.n. and i.t. routes with SARS-CoV at a tissue culture 50% infectious dose (TCID50) of 10^6 per site. (DiNapoli et al., 2007)
• Efficacy: Protected (DiNapoli et al., 2007)
• Description: Immunization with NDV-VF/S resulted in a 5-fold and 61-fold reduction in nasal turbinate and tracheal SARS-CoV titers, respectively, compared with the control animals. (DiNapoli et al., 2007)